MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, announced today that Mike Lawless, Chief Financial Officer, will provide an overview presentation and host one-on-one meetings with investors at the ThinkEquity Conference on October 30, 2024.
The presentation will begin at 3:00 PM EDT on October 30 and can be accessed on the Investor Relations section of the Lifeward website or at the following link: https://wsw.com/webcast/tep25/lfwd/1675728. A replay of the presentation will be available for 90 days following the event.
About Lifeward
Lifeward designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our mission at Lifeward is to relentlessly drive innovation to change the lives of individuals with physical limitations or disabilities. We are committed to delivering groundbreaking solutions that empower individuals to do what they love. The Lifeward portfolio features innovative products including the ReWalk Exoskeleton, the AlterG Anti-Gravity system, the MyoCycle FES System, and the ReStore Exo-Suit.
Founded in 2001, Lifeward has operations in the United States, Israel, and Germany. For more information on the Lifeward product portfolio, please visit GoLifeward.com.
ReWalk®, ReStore® and Alter G® are registered trademarks of Lifeward Ltd. and/or its affiliates.
Lifeward Media Relations:
Kathleen O’Donnell
VP Marketing & New Business Development
Lifeward
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
Lifeward Investor Contact:
Mike Lawless
Chief Financial Officer
Lifeward
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.50 |
Daily Change: | 0.01 0.67 |
Daily Volume: | 64,719 |
Market Cap: | US$13.220M |
November 12, 2024 September 24, 2024 September 04, 2024 August 15, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB